We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I...
VANCOUVER, Wash. and BARCELONA, Spain, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and Almirall S.A. (BME: ALM), a global...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0.14 | 0.14 | 0.14 | 1000 | 0.14 | CS |
12 | 0.07 | 100 | 0.07 | 0.14 | 0.07 | 34380 | 0.09942602 | CS |
26 | 0.055 | 64.7058823529 | 0.085 | 0.14 | 0.07 | 50275 | 0.09512902 | CS |
52 | -0.08 | -36.3636363636 | 0.22 | 0.22 | 0.07 | 32696 | 0.12650226 | CS |
156 | -0.18 | -56.25 | 0.32 | 1.15 | 0.07 | 19163 | 0.30683573 | CS |
260 | 0.13 | 1300 | 0.01 | 1.15 | 0.005 | 85796 | 0.05274239 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions